ALX ONCOLOGY HLDGS INC's ticker is ALXO and the CUSIP is 00166B105. A total of 76 filers reported holding ALX ONCOLOGY HLDGS INC in Q2 2023. The put-call ratio across all filers is 0.13 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $4,839,533 | -36.0% | 1,008,236 | +0.2% | 0.00% | – |
Q2 2023 | $7,559,476 | +61.5% | 1,006,588 | -2.8% | 0.00% | – |
Q1 2023 | $4,680,637 | -70.9% | 1,035,539 | -27.3% | 0.00% | – |
Q4 2022 | $16,063,109 | +19.0% | 1,425,298 | +1.0% | 0.00% | – |
Q3 2022 | $13,503,000 | +26.0% | 1,411,009 | +6.5% | 0.00% | – |
Q2 2022 | $10,717,000 | -62.2% | 1,324,737 | -20.9% | 0.00% | -100.0% |
Q1 2022 | $28,318,000 | -22.8% | 1,675,656 | -1.9% | 0.00% | 0.0% |
Q4 2021 | $36,705,000 | -70.4% | 1,708,034 | +1.7% | 0.00% | -66.7% |
Q3 2021 | $124,049,000 | +46.4% | 1,679,528 | +8.4% | 0.00% | +50.0% |
Q2 2021 | $84,738,000 | -15.3% | 1,549,718 | +14.2% | 0.00% | -33.3% |
Q1 2021 | $100,074,000 | +31.4% | 1,357,108 | +53.6% | 0.00% | +50.0% |
Q4 2020 | $76,136,000 | +212.6% | 883,262 | +36.9% | 0.00% | +100.0% |
Q3 2020 | $24,357,000 | – | 645,382 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
venBio Partners LLC | 9,699,925 | $715,272,000 | 67.97% |
Logos Global Management LP | 3,156,981 | $232,796,000 | 22.72% |
Vivo Capital, LLC | 4,220,048 | $311,186,000 | 10.94% |
Foresite Capital Management IV, LLC | 785,945 | $57,956,000 | 6.94% |
Foresite Capital Management V, LLC | 320,000 | $23,597,000 | 6.94% |
Board of Trustees of The Leland Stanford Junior University | 518,822 | $38,258,000 | 3.38% |
Cormorant Asset Management, LP | 881,770 | $65,022,000 | 1.45% |
Redmile Group, LLC | 978,600 | $72,162,000 | 1.02% |
SPHERA FUNDS MANAGEMENT LTD. | 130,351 | $9,612,000 | 0.74% |
Artal Group S.A. | 525,000 | $38,714,000 | 0.68% |